Coronavirus Outbreak: WHO pauses trial of hydroxychloroquine over safety concerns, clinical tests of other potential treatments to continue
The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns
Geneva: The World Health Organization (WHO) has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The US President has said he was taking the drug to help prevent infection.
“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.
He said the other arms of the trial - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.
The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.
Dr Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution”.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
COVAXIN controversy: Bharat Biotech-ICMR readying a COVID-19 vaccine in 45 days baffles reason, ignores safety concerns, says bioethicist
Dr Anant Bhan, a researcher in global health, bioethics and health policy and former president of International Association of Bioethics, spoke to Firstpost about the "extreme urgency" shown by ICMR in developing India's COVID-19 vaccine, COVAXIN, by 15 August
COVAXIN controversy: Doctors in trial sites chosen by ICMR say human trials can’t be fast forwarded, anticipate 6-month observation period
Hyderabad-based Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) to begin human trials of COVAXIN last week. The vaccine has been developed in collaboration with the ICMR and National Institute of Virology in Pune.
Bharat Biotech has passed mandated protocols, animal testing and is now in clinical development of Covid vaccine, Dr Krishna Ella tells Firstpost
Hyderabad-based Bharat Biotech, one of seven Indian companies involved in the indigenous production of a vaccine for the novel coronavirus, received the green signal from the Central Drugs Standard Control Organisation (CDSCO) to begin human trials of 'Covaxin' last week.